Top

Published in:

Open Access 01-01-2021 | Prostate Cancer | Topic Paper

Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment

Authors: Rebecca Roth, Sebastian Dieng, Alisa Oesterle, Günter Feick, Günther Carl, Andreas Hinkel, Thomas Steiner, Björn Theodor Kaftan, Frank Kunath, Boris Hadaschik, Simba-Joshua Oostdam, Rein Jüri Palisaar, Mateusz Koralewski, Burkhard Beyer, Björn Haben, Igor Tsaur, Simone Wesselmann, Christoph Kowalski

Published in: World Journal of Urology | Issue 1/2021

Abstract

Purpose

The self-reported functional status (sr-FS) of prostate cancer (PCa) patients varies substantially between patients and health-care providers before treatment. Information about this issue is important for evaluating comparisons between health-care providers and to assist in treatment decision-making. There have been few reports on correlates of pretherapeutic sr-FS. The objective of the article, therefore, is to describe clinical and sociodemographic correlates of pretherapeutic sr-FS, based on a subset of the TrueNTH Global Registry, a prospective cohort study.

Methods

A total of 3094 PCa patients receiving local treatment in 44 PCa centers in Germany were recruited between July 2016 and April 2018. Multilevel regression models were applied to predict five pretherapeutic sr-FS (EPIC-26) scores based on clinical characteristics (standard set suggested by the International Consortium for Health Outcomes Measurement), sociodemographic characteristics, and center characteristics.

Results

Impaired pretherapeutic sr-FS tended to be associated with lower educational level and poorer disease characteristics—except for “urinary incontinence” which was only associated with age. Notably, age was a risk factor (“urinary incontinence,” “urinary irritative/obstructive,” “sexual”) as well as a protective factor (“hormonal”) for pretherapeutic sr-FS. Pretherapeutic sr-FS varies little across centers.

Conclusions

Pretherapeutic sr-FS varies by clinical patient characteristics and age as well as by socioeconomic status. The findings point out the benefit of collecting and considering socioeconomic information in addition to clinical and demographic patient characteristics for treatment decision-making and fair comparisons between health-care providers.

Available only for authorised users

Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF (2015) The evolution of self-reported urinary and sexual dysfunction over the last two decades: implications for comparative effectiveness research. Eur Urol 67(6):1019–1025. https://doi.org/10.1016/j.eururo.2014.08.035CrossRefPubMed

Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814–822. https://doi.org/10.1001/jama.2013.879CrossRefPubMed

Klinkhammer-Schalke M, Koller M, Steinger B, Ehret C, Ernst B, Wyatt JC, Hofstadter F, Lorenz W, Regensburg Qo LSG (2012) Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer. Br J Cancer 106(5):826–838. https://doi.org/10.1038/bjc.2012.4CrossRefPubMedPubMedCentral

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565. https://doi.org/10.1200/JCO.2015.63.0830CrossRefPubMed

Hartz A, He T, Strope S, Cutler DR, Andriole G, Dechet C (2013) Surgeon variation in patient quality of life after radical prostatectomy. J Urol 189(4):1295–1301. https://doi.org/10.1016/j.juro.2012.10.118CrossRefPubMed

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, Ogunbiyi OJ, Azevedo ESG, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England) 391(10125):1023–1075. https://doi.org/10.1016/s0140-6736(17)33326-3CrossRefPubMedCentral

Zaider T, Manne S, Nelson C, Mulhall J, Kissane D (2012) Loss of masculine identity, marital affection, and sexual bother in men with localized prostate cancer. J Sex Mede 9(10):2724–2732. https://doi.org/10.1111/j.1743-6109.2012.02897.xCrossRef

Lucas SM, Kim TK, Ghani KR, Miller DC, Linsell S, Starr J, Peabody JO, Hurley P, Montie J, Cher ML (2017) Establishment of a web-based system for collection of patient-reported outcomes after radical prostatectomy in a statewide quality improvement collaborative. Urology 107:96–102. https://doi.org/10.1016/j.urology.2017.04.058CrossRefPubMed

Beyer B, Mandel P, Michl U, Pompe RS, Veleva V, Steuber T, Huland H, Graefen M, Tilki D (2016) Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy. World J Urol 34(8):1101–1105. https://doi.org/10.1007/s00345-015-1758-2CrossRefPubMed

10.

Jacobs BL, Lopa SH, Yabes JG, Nelson JB, Barnato AE, Degenholtz HB (2016) Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population. Cancer 122(20):3199–3206. https://doi.org/10.1002/cncr.30184CrossRefPubMedPubMedCentral

11.

Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EAS, Guedea F, Cvancarova M, Fosså SD (2014) Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment. Clin Genitourin Cancer 12(4):e117–e125. https://doi.org/10.1016/j.clgc.2013.12.007CrossRefPubMedPubMedCentral

12.

Marmot M (2005) Social determinants of health inequalities. Lancet 365(9464):1099–1104. https://doi.org/10.1016/s0140-6736(05)74234-3CrossRefPubMed

13.

Kowalski C, Hein R, Carl G, Feick G, Oesterle A, Hinkel A, Steiner T, Brock M, Kaftan B, Borowitz R, Zantl N, Heidenreich A, Neisius A, Darr C, Bolenz C, Beyer B, Pfitzenmaier J, Brehmer B, Fichtner J, Haben B, Wesselmann S, Dieng S (submitted) Implementing a multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: design and progress report.

14.

Evans SM, Millar JL, Moore CM, Lewis JD, Huland H, Sampurno F, Connor SE, Villanti P, Litwin MS (2017) Cohort profile: the TrueNTH Global Registry—an international registry to monitor and improve localised prostate cancer health outcomes. BMJ Open 7(11):e017006. https://doi.org/10.1136/bmjopen-2017-017006CrossRefPubMedPubMedCentral

15.

Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S (2016) Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol 34(5):665–672. https://doi.org/10.1007/s00345-015-1688-zCrossRefPubMed

16.

Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67(3):460–467. https://doi.org/10.1016/j.eururo.2014.08.075CrossRefPubMed

17.

Sibert NT, Dieng S, Oesterle A, Feick G, Carl G, Steiner T, Minner J, Roghmann F, Kaftan B, Zengerling F, Hinkel A, Beyer B, Heidenreich A, Harke N, Brehmer B, Pfitzenmaier J, Fichtner J, Neisius A, Hammerer P, Wesselmann S, Kowalski C (2019) Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer. World J Urol. https://doi.org/10.1007/s00345-019-02949-7CrossRefPubMed

18.

Sanda MG, Wei JT, Litwin MS (2002) Scoring instructions for the expanded prostate cancer index composite schort form (EPIC-26). The Universityy of Michigan, Ann Arbor

19.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2018) [Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0].

20.

Core Team R (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

21.

Bates D, Mächler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw. https://doi.org/10.18637/jss.v067.i01CrossRef

22.

Venables WN, Ripley BD (2002) Modern applied statistics with S, 4th edn. Springer, New YorkCrossRef

23.

Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF (2014) Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: defining the population at risk for harms of prostate cancer treatment. Cancer 120(8):1263–1271. https://doi.org/10.1002/cncr.28563CrossRefPubMedPubMedCentral

24.

Rezaei N, Azadi A, Pakzad R (2018) Prevalence of andropause among Iranian men and its relationship with quality of life. Aging Male. https://doi.org/10.1080/13685538.2018.1490951CrossRefPubMed

25.

Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2019) Interpretation of Domain Scores on the EPIC: How Does the Domain Score Translate into Functional Outcomes? The Journal of urology:101097ju0000000000000392. doi:10.1097/ju.0000000000000392

26.

Barocas DA, Alvarez J, Resnick MJ et al (2017) Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 317(11):1126–1140. https://doi.org/10.1001/jama.2017.1704CrossRefPubMedPubMedCentral

27.

Herden J, Ansmann L, Ernstmann N, Schnell D, Weissbac L (2016) The treatment of localized prostate cancer in everyday practice in Germany. Dtsch Arztebl Int 113(19):329–336. https://doi.org/10.3238/arztebl.2016.0329CrossRefPubMedPubMedCentral

28.

Klein J, Ovd K (2015) Socioeconomic inequalities in prostate cancer survival: a review of the evidence and explanatory factors. Soc Sci Med. https://doi.org/10.1016/j.socscimed.2015.07.006CrossRefPubMed

Title: Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment
Authors: Rebecca Roth
Sebastian Dieng
Alisa Oesterle
Günter Feick
Günther Carl
Andreas Hinkel
Thomas Steiner
Björn Theodor Kaftan
Frank Kunath
Boris Hadaschik
Simba-Joshua Oostdam
Rein Jüri Palisaar
Mateusz Koralewski
Burkhard Beyer
Björn Haben
Igor Tsaur
Simone Wesselmann
Christoph Kowalski
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Urinary Incontinence
Urinary Incontinence
Published in: World Journal of Urology / Issue 1/2021
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-020-03097-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The “Omega Sign”: a novel HoLEP technique that improves continence outcomes after enucleation

Development of bioabsorbable zinc–magnesium alloy wire and validation of its application to urinary tract surgeries

Tolvaptan treatment of cystine urolithiasis in a mouse model of cystinuria

Outcome of simultaneous thulium laser enucleation of bladder tumor and prostate in patients with non-muscle invasive bladder tumor and benign prostatic hyperplasia: a matched-pair comparison with a long-term follow-up

Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial

Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria